Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Cash & Equivalents (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Cash & Equivalents readings, the most recent being $6137.0 for Q4 2025.

  • Quarterly Cash & Equivalents rose 354.26% to $6137.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6137.0 through Dec 2025, up 354.26% year-over-year, with the annual reading at $6137.0 for FY2025, 354.26% up from the prior year.
  • Cash & Equivalents hit $6137.0 in Q4 2025 for Drugs Made In America Acquisition, up from $717.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $6137.0 in Q4 2025 and bottomed at $717.0 in Q3 2025.